Should fosamprenavir be considered the 'third' agent for first line or first PI therapy?

Español (soon!) - January 5, 2009

CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.

Conference

"Should fosamprenavir be considered the 'third' agent for first line or first PI therapy?"
Dr. Sharon Walmsley (biography)
English - 2007-03-16 - 55 minutes

(52 slides)

Learning objectives :
After viewing this presentation the participant will be able to discuss:

- Pivotal studies of boosted fosamprenavir (FPV/r) as first PI
- FPV/r resistance in antiretroviral-naïve subjects
- Does the use of FPV as first PI compromise the use of darunavir?
- Pharmacokinetics of FPV when used with antacids
- Patient-reported body composition changes with FPV/r

Login

	Please log in and get access to thousands of resources about HIV disease and its treatment.
	Already a member?
	Username :
	Password :

	Lost your password?

Search our database

Find the information that you are looking for in over +3000 resources.

ezCME: HIV - Insulin Resistance - C-Reactive Protein (CRP) - ADHD - Sleep Disorder - Prostate Health - Hemophilia - Transplantation

CMEonHIV is owned by E-MedHosting.com.

Copyright @ 2002-2009 E-MedHosting.com. All rights reserved. Disclaimer | Sponsor Disclaimer
Powered by Multiwebcast - webcast services

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR
BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.